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Background:  There  are  few data  regarding  the  effect  of  statins  on  regression  and  compositional  changes  of
plaque  according  to the reduction  in  high-sensitivity  C-reactive  protein  (hs-CRP)  levels  in  acute  myocar-
dial infarction  (AMI)  patients.
Methods:  We  used  serial  virtual  histology-intravascular  ultrasound  to  assess  the  efﬁcacy  of  pitavastatin
(dosage:  2  mg/day)  on  plaque  regression  and  compositional  changes  according  to  the  degree  of  reduction
in hs-CRP  levels  from  baseline  to  follow-up  [≥1  mg/dl  (n = 62) vs. <1 mg/dl  (n  = 32)]  in  non-intervened
non-infarct  related  artery  in  AMI patients  who  were  enrolled  in  the  Livalo  in  acute  myocardial  infarction
study  (LAMIS).
Results:  Total  atheroma  and  percent  atheroma  volumes  decreased  more  signiﬁcantly  in patients  with
reduction  in  hs-CRP  ≥1  mg/dl  compared  with  those  with  reduction  in  hs-CRP  <1 mg/dl  (−1.7  ±  12.4  mm3
vs.  +2.7  ± 7.8  mm3, p < 0.015,  and  −0.4 ± 3.4%  vs. +0.4 ±  4.8%,  p < 0.001,  respectively).  Absolute  and
%necrotic  core  volumes  decreased  more  signiﬁcantly  in  patients  with  reduction  in  hs-CRP  ≥1 mg/dl  com-
pared with  those  with  reduction  in hs-CRP  <1  mg/dl  (−0.4  ±  3.5  mm3 vs.  +1.9  ±  3.4 mm3, p =  0.038,  and
−1.1  ±  4.9%  vs.  +2.7  ± 4.7%,  p =  0.016,  respectively).  Reduction  in  hs-CRP  ≥1  mg/dl  at follow-up  was  the
independent  predictor  of reduction  of  percent  atheroma  volume  and  %necrotic  core  volume  at  follow-
up  [odds  ratio  (OR),  2.228;  95%  conﬁdence  interval  (CI),  1.390–2.977,  p = 0.016,  and  OR,  2.204;  95% CI,
1.512–2.916,  p  =  0.020,  respectively].
Conclusions:  Reduction  in  hs-CRP  levels  in  AMI patients  plays  an  important  role  in  the  beneﬁcial  effects
of  statins  on  the regression  and  compositional  change  of  coronary  plaque.
2  Jap©  201
. IntroductionPitavastatin (Livalo®, Kowa, Nagoya, Japan) is a 3-hydroxy-3-
ethylglutaryl-coenzyme A reductase inhibitor that signiﬁcantly
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reduces the levels of plasma low-density lipoprotein cholesterol
and modestly increases levels of high-density lipoprotein choles-
terol [1]. Statins have a wide range of biologic effects in addition to
lipid lowering, including reductions in the levels of C-reactive pro-
tein (CRP), a phenomenon commonly termed a “pleiotropic effect”
[2–4].Vascular inﬂammation plays an important role in atherogenesis
and thrombotic events [5].  High-sensitivity (hs)-CRP has been
associated with high risk for the development of coronary artery
disease [6],  and hs-CRP has emerged as a simple tool for detecting
vier Ltd. All rights reserved.
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Pearson correlation was used to evaluate the correlation between
change ()  of hs-CRP from baseline to follow-up and change of PAV
and between change of hs-CRP from baseline to follow-up and %NC78 Y.J. Hong et al. / Journal of
ystemic inﬂammation in patients with subsequent coronary
vents [7,8]. Measurement of hs-CRP has been recommended for
atients to reﬁne risk assessment [9].
There are limited data regarding the effect of pitavastatin on
egression and compositional changes of plaque according to the
eduction in hs-CRP levels in acute myocardial infarction (AMI)
atients. Therefore, the aim of this study was to assess the efﬁcacy
f pitavastatin on plaque regression and compositional changes
ccording to the degree of reduction in hs-CRP levels at follow-up
n non-intervened non-infarct related artery in AMI  patients who
ere enrolled in the Livalo® in acute myocardial infarction study
LAMIS).
. Methods
.1. Patient population
LAMIS is a substudy of the Korea Acute Myocardial Infarction
egistry (KAMIR). The KAMIR is a Korean prospective multicen-
er online registry designed to reﬂect the “real-world” practice in
sian patients presenting with AMI  including both ST segment ele-
ation MI  and non-ST segment elevation MI  with support from the
orean Circulation Society since November 2005 [10,11].  Online
egistry of AMI (at http://www.kamir.or.kr) has been performed at
2 university or community hospitals that are high-volume centers
ith facilities for primary percutaneous coronary intervention and
nsite cardiac surgery. The LAMIS investigators were selected from
0 major percutaneous coronary intervention centers among the 52
AMIR sites and 1039 consecutive AMI  patients who  received 2 mg
f pitavastatin daily as a sole statin were prospectively enrolled
etween February 2007 and September 2009. Of these patients,
 total of 94 who underwent baseline and follow-up gray-scale
ntravascular ultrasound (IVUS) and virtual histology (VH)-IVUS
or non-intervened non-infarct related artery and checked baseline
nd follow-up hs-CRP were included in this VH-IVUS substudy. The
ata were analyzed at quantitative coronary angiography (QCA)
nd IVUS core laboratory (Chonnam National University Hospital).
e divided the patients into two groups according to the degree of
he reduction in hs-CRP levels from baseline to follow-up [≥1 mg/dl
n = 62) vs. <1 mg/dl (n = 32)]. The selected value of 1 mg/dl as a clas-
iﬁcation border of the degree of hs-CRP reduction was determined
n the basis of the median change in hs-CRP of 1.01 mg/dl. The
resence of ST-segment elevation MI  was determined by >30 min
f continuous chest pain, a new ST-segment elevation ≥2 mm on at
east 2 contiguous electrocardiographic leads, and creatine kinase-
B >3 times normal. The presence of non-ST-segment elevation
I was diagnosed by chest pain and a positive cardiac biochemical
arkers (creatine kinase-MB or cardiac speciﬁc troponin-I) without
ew ST-segment elevation. The protocol was approved by the insti-
utional review board. Hospital records of patients were reviewed
o obtain information on clinical demographics.
.2. Laboratory analysis
Venous blood samples were obtained before IVUS study within
4 h of symptom onset. The blood samples were centrifuged, and
erum was removed and stored at −70 ◦C until the assay could
e performed. hs-CRP was  assessed by the immunoturbidimet-
ic CRP-Latex (II) hs assay using an Olympus 5431 autoanalyzer
Olympus, Tokyo, Japan). The assay was performed according to
he manufacturer’s protocol and has been validated against the
ade-Behring method [12]. This assay has a coefﬁcient of varia-
ion of ≈5%. Absolute creatine kinase-MB levels were determined
y radioimmunoassay (Dade Behring Inc., Miami, FL, USA). Cardiac-
peciﬁc troponin I levels were measured by a paramagnetic particle,ology 60 (2012) 277–282
chemiluminescent immunoenzymatic assay (Beckman, Coulter
Inc., Fullerton, CA, USA). The serum levels of total cholesterol,
triglyceride, low-density lipoprotein cholesterol, and high-density
lipoprotein cholesterol were measured by standard enzymatic
methods.
2.3. Angiographic analysis
Coronary angiogram was  analyzed with validated QCA system
(Phillips H5000 or Allura DCI program, Philips Medical Systems,
Eindhoven, the Netherlands). With the outer diameter of the
contrast-ﬁlled catheter as the calibration standard, the minimal
lumen diameter and reference diameter were measured in diastolic
frames from orthogonal projections.
2.4. IVUS imaging and analysis
All gray-scale and VH-IVUS examinations were performed after
intracoronary administration of 300 g nitroglycerin. A 20-MHz,
2.9F IVUS imaging catheter (Eagle Eye, Volcano Corp, Rancho Cor-
dova, CA, USA) was advanced >10 mm beyond the lesion; and
automated pullback was performed to a point >10 mm proximal
to the lesion at a speed of 0.5 mm/s.
A single operator blinded to the clinical presentation analyzed
the IVUS images and measured diseased segment (normal to nor-
mal). The same anatomic image slices were analyzed at baseline
and at follow-up. By using the axial landmark (i.e. side branch,
calciﬁcations, or unusual plaque shapes) and the known pull-
back speed, identical cross-sectional image slices on serial studies
could be identiﬁed for comparison. We  measured IVUS images
spaced precisely 1 mm apart. The leading edges of the external
elastic membrane (EEM) and lumen were traced manually using
planimetry software (Echoplaque 3.0, INDEC Systems, Santa Clara,
CA, USA) in accordance with guidelines for IVUS from the Ameri-
can College of Cardiology Clinical Expert Consensus Document on
Standards for Acquisition, Measurement and Reporting of Intravas-
cular Ultrasound Studies [13]. TAV was  calculated by summation
of atheroma area from each measured image as: TAV = (EEM
area − lumen area). The percent atheroma volume (PAV) was
determined using the formula: PAV = 100 × [(EEM area − lumen
area)/(EEM area)].
VH-IVUS analysis classiﬁed the color-coded tissue into four
major components: green (ﬁbrotic); yellow-green (ﬁbro-fatty, FF);
white (dense calcium); and red (necrotic core, NC) [14,15].  VH-IVUS
analysis was  reported in absolute amounts and as a percentage of
plaque volume.
2.5. Statistical analysis
The statistical Package for Social Sciences (SPSS) for Windows,
version 15.0 (Chicago, IL, USA) was  used for all analyses. Continuous
variables were presented as the mean value ± 1SD; comparisons
were conducted by Student’s t-test or the Wilcoxon rank-sum
test if normality assumption was violated. Discrete variables were
presented as percentages and frequencies; comparisons were con-
ducted by chi-square statistics or Fisher’s exact test as appropriate.volume from baseline to follow-up. Multivariable logistic regres-
sion analysis was performed to identify the independent predictors
of PAV reduction and %NC volume reduction at follow-up. A p-value
<0.05 was  considered statistically signiﬁcant.
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Table  1
Baseline characteristics.
hs-CRP reduction
<1 mg/dl (n = 32)
hs-CRP reduction
≥1 mg/dl (n = 62)
p-Value
Age (years) 64 ± 12 63 ± 9 0.5
Male gender 24 (75) 44 (71) 0.7
Clinical presentation 0.5
STEMI 24 (75) 42 (68)
NSTEMI 8 (25) 20 (32)
Diabetes mellitus 12 (38) 20 (32) 0.6
Hypertension 22 (69) 42 (68) 0.9
Smoking 18 (56) 30 (48) 0.8
Ejection fraction (%) 47 ± 9 45 ± 8 0.2
Creatine kinase-MB (U/l) 14 ± 36 16 ± 42 0.6
Troponin-I (ng/ml) 5.3 ± 17.7 6.7 ± 35.1 0.6
Creatinine (mg/dl) 0.96 ± 0.40 0.99 ± 0.77 0.8
hs-CRP (mg/dl) 0.20 ± 0.31 2.41 ± 4.32 0.001
Total cholesterol (mg/dl) 170 ± 24 195 ± 41 0.001
Triglyceride (mg/dl) 120 ± 70 161 ± 145 0.036
LDL  cholesterol (mg/dl) 111 ± 20 123 ± 33 <0.001
HDL cholesterol (mg/dl) 47± 10 44± 9 0.13
Apolipoprotein A1
(mg/dl)
134 ± 20 113 ± 14 <0.001
Apolipoprotein B
(mg/dl)
80 ± 18 94 ± 27 0.099
Lipoprotien (a) (mg/dl) 32± 27 37± 27 0.001
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Table 2
Coronary angiographic and intravascular ultrasound ﬁndings.
hs-CRP reduction
<1 mg/dl (n = 32)
hs-CRP reduction
≥1 mg/dl (n = 62)
p-Value
Target vessel 0.11
Left main 12 (38) 14 (23)
Left anterior
descending
12 (38) 20 (32)
Left circumﬂex 4 (13) 6 (10)
Right 4 (13) 22 (36)
Reference diameter
(mm)
3.27 ± 0.57 3.32 ± 0.56 0.5
Minimal lumen
diameter (mm)
1.67 ± 0.63 1.56 ± 0.61 0.4
Percent diameter
stenosis (%)
49 ± 10 53 ± 11 0.2
IVUS lesion length (mm) 21 ± 13 24 ± 15 0.4
EEM volume (mm3) 182 ± 95 196 ± 153 0.6
Lumen volume (mm3) 94 ± 59 89 ± 63 0.7
Total atheroma volume
(mm3)
88 ± 46 106 ± 92 0.2
Percent atheroma
volume (%)
49.1 ± 10.5 51.1 ± 10.2 0.4
Absolute FT volume
(mm3)
41.6 ± 24.5 39.0 ± 44.8 0.8
Absolute FF volume
(mm3)
11.4 ± 7.5 7.4 ± 12.2 0.18
Absolute DC volume
(mm3)
5.6 ± 8.0 5.4 ± 5.0 0.9
Absolute NC volume
(mm3)
6.6 ± 7.1 12.3 ± 12.5 0.024
Relative FT volume (%) 63.8 ± 9.6 60.8 ± 10.5 0.10
Relative FF volume (%) 17.5 ± 8.1 11.5 ± 6.2 0.001
Relative DC volume (%) 8.6 ± 8.1 8.4 ± 6.4 0.9
Relative NC volume (%) 10.1 ± 7.0 19.2 ± 11.0 <0.001
Data are n (%), or mean ± SD. hs-CRP, high-sensitivity C-reactive protein; IVUS,
intravascular ultrasound; EEM, external elastic membrane; FT, ﬁbrotic; FF, ﬁbro-
fatty; DC, dense calcium; NC, necrotic core.
Table 3
Follow-up laboratory and intravascular ultrasound ﬁndings.
hs-CRP reduction
<1 mg/dl (n = 32)
hs-CRP reduction
≥1 mg/dl (n = 62)
p-Value
hs-CRP (mg/dl) 0.19 ± 0.35 0.26 ± 0.36 0.4
Total cholesterol (mg/dl) 134 ± 24 149 ± 26 0.013
Triglyceride (mg/dl) 107 ± 54 148 ± 80 0.015
LDL  cholesterol (mg/dl) 80 ± 17 89 ± 22 0.076
HDL cholesterol (mg/dl) 46 ± 13 42 ± 10 0.13
Apoprotein A1 (mg/dl) 128 ± 24 133 ± 30 0.6
Apoprotein B (mg/dl) 58 ± 10 65 ± 9 0.043
Lipoprotein (a) (mg/dl) 30 ± 19 35 ± 29 0.001
EEM volume (mm3) 184 ± 92 193 ± 149 0.7
Lumen volume (mm3) 94 ± 56 91 ± 63 0.9
Total atheroma volume
(mm3)
90 ± 45 102 ± 89 0.4
Percent atheroma
volume (%)
49.5 ± 10.8 50.0 ± 9.7 0.8
Absolute FT volume
(mm3)
40.8 ± 20.1 39.1 ± 41.0 0.8
Absolute FF volume
(mm3)
11.3 ± 4.2 8.2 ± 11.5 0.4
Absolute DC volume
(mm3)
5.8 ± 8.1 6.5 ± 8.7 0.2
Absolute NC volume
(mm3)
8.5 ± 11.4 11.9 ± 7.8 0.034
Relative FT volume (%) 61.4 ± 14.1 59.5 ± 12.9 0.9
Relative FF volume (%) 17.0 ± 5.1 12.4 ± 8.1 0.019
Relative DC volume (%) 8.7 ± 8.1 9.9 ± 6.9 0.2
Relative NC volume (%) 12.8 ± 10.4 18.1 ± 11.6 0.016ata are n (%), or mean ± SD. hs-CRP, high-sensitivity C-reactive protein; STEMI,
T  segment elevation myocardial infarction; NSTEMI, non-ST segment elevation
yocardial infarction; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
. Results
.1. Baseline characteristics
The baseline characteristics are summarized in Table 1. hs-CRP
evel was 2.41 ± 4.32 mg/dl in patients with reduction in hs-CRP
1 mg/dl and 0.20 ± 0.31 mg/dl in patients with reduction in hs-CRP
1 mg/dl. There were no signiﬁcant differences in clinical pre-
entation and prevalence of diabetes mellitus and hypertension
nd cardiac enzyme levels between both groups. Baseline total
holesterol, triglyceride, low-density lipoprotein cholesterol, and
ipoprotein (a) levels were signiﬁcantly higher in patients with
eduction in hs-CRP ≥1 mg/dl compared with those with reduction
n hs-CRP <1 mg/dl.
.2. Coronary angiographic and IVUS ﬁndings
Coronary angiographic and IVUS ﬁndings are summarized in
able 2. There were no signiﬁcant differences in the target ves-
el, reference diameter, minimal lumen diameter, and percent
iameter stenosis between both groups. There were no signiﬁcant
ifferences in IVUS lesion length, and TAV and PAV between both
roups. Absolute and %NC volumes were signiﬁcantly greater and
FF volume was signiﬁcantly smaller in patients with reduction in
s-CRP ≥1 mg/dl compared with those with reduction in hs-CRP
1 mg/dl.
.3. Follow-up laboratory and IVUS ﬁndings
Follow-up laboratory and IVUS ﬁndings are summarized in
able 3. Follow-up duration was 8.1 ± 2.2 months in patients with
eduction in hs-CRP ≥1 mg/dl and 8.3 ± 1.7 months in patients with
eduction in hs-CRP <1 mg/dl. Follow-up hs-CRP, total cholesterol,
riglyceride, apolipoprotein B, and lipoprotein (a) levels were sig-
iﬁcantly greater in patients with reduction in hs-CRP ≥1 mg/dl
ompared with those with reduction in hs-CRP <1 mg/dl. Absolute
nd %NC volumes were signiﬁcantly greater and %FF volume was
igniﬁcantly smaller in patients with reduction in hs-CRP ≥1 mg/dl
ompared with those with reduction in hs-CRP <1 mg/dl.
Data are n (%), or mean ± SD. hs-CRP, high-sensitivity C-reactive protein; LDL,
low-density lipoprotein; HDL, high-density lipoprotein; EEM, external elastic mem-
brane; FT, ﬁbrotic; FF, ﬁbro-fatty; DC, dense calcium; NC, necrotic core.
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Table  4
Changes in laboratory ﬁndings, intravascular ultrasound ﬁndings from baseline to
follow-up.
hs-CRP reduction
<1 mg/dl (n = 32)
hs-CRP reduction
≥1 mg/dl (n = 62)
p-Value
hs-CRP (mg/dl) −0.01 ± 0.11 −2.68 ± 4.90 0.003
Total  cholesterol (mg/dl) −38 ± 29 −45 ± 32 0.3
Triglyceride (mg/dl) −18 ± 33 −33 ± 71 0.11
LDL  cholesterol (mg/dl) −33 ± 22 −34 ± 26 0.9
HDL  cholesterol (mg/dl) −0.8 ± 8.2 −1.9 ± 10.0 0.6
Apoprotein A1 (mg/dl) −6 ± 8 +17± 27 0.001
Apoprotein B (mg/dl) −22 ± 19 −28 ± 17 0.3
Lipoprotein (a) (mg/dl) −2 ± 6 −2 ± 5 0.9
EEM  volume (mm3) +2.3 ± 8.8 −0.3 ± 14.7 <0.001
Lumen volume (mm3) −0.4 ± 10.5 +1.5 ± 6.1 0.021
Total  atheroma volume
(mm3)
+2.7 ± 7.8 −1.7 ± 12.4 <0.001
Percent atheroma
volume (%)
+0.4 ± 4.8 −0.4 ± 3.4 <0.001
Absolute FT volume
(mm3)
−0.8 ± 3.1 +0.1 ± 3.4 0.2
Absolute FF volume
(mm3)
+0.1 ± 3.4 +0.8 ± 3.9 0.15
Absolute DC volume
(mm3)
+0.2 ± 2.3 +1.1 ± 2.8 0.6
Absolute NC volume
(mm3)
+1.9 ± 3.4 −0.4 ± 3.5 0.038
Relative FT volume (%) −2.4 ± 4.2 −1.3 ± 4.6 0.2
Relative FF volume (%) +0.5 ± 4.5 +0.9 ± 4.2 0.5
Relative DC volume (%) +0.1 ± 4.5 +1.5 ± 4.2 0.10
Relative NC volume (%) +2.7 ± 4.7 −1.1 ± 4.9 0.016
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aata are n (%), or mean ± SD. hs-CRP, high-sensitivity C-reactive protein; LDL,
ow-density lipoprotein; HDL, high-density lipoprotein; EEM, external elastic mem-
rane; FT, ﬁbrotic; FF, ﬁbro-fatty; DC, dense calcium; NC, necrotic core.
.4. Changes in laboratory and IVUS ﬁndings from baseline to
ollow-up
Changes in laboratory and IVUS ﬁndings from baseline to follow-
p are summarized in Table 4. The change in hs-CRP level from
aseline to follow-up was  −2.68 ± 4.90 mg/dl in patients with
eduction in hs-CRP ≥1 mg/dl and −0.01 ± 0.11 mg/dl in patients
ith reduction in hs-CRP <1 mg/dl. TAV and PAV decreased more
igniﬁcantly in patients with reduction in hs-CRP ≥1 mg/dl com-
ared with those with reduction in hs-CRP <1 mg/dl. Absolute and
NC volumes decreased more signiﬁcantly in patients with reduc-
ion in hs-CRP ≥1 mg/dl compared with those with reduction in
s-CRP <1 mg/dl. Change in hs-CRP from baseline to follow-up cor-
elated with change in PAV (r = 0.372, p = 0.005) and %NC volume
rom baseline to follow-up (r = 0.385, p = 0.002).
.5. Independent predictors of reduction in PAV and %NC volume
The following variables were tested to determine the indepen-
ent predictors of PAV reduction at follow-up (variables with p < 0.1
n univariable analysis): reduction in hs-CRP ≥1 mg/dl at follow-up,
iabetes mellitus, baseline PAV, follow-up low-density lipopro-
ein cholesterol. Reduction in hs-CRP ≥1 mg/dl at follow-up and
ollow-up low-density lipoprotein cholesterol were the indepen-
ent predictors for PAV reduction [odds ratio (OR), 2.228; 95%
onﬁdence interval (CI), 1.390–2.977, p = 0.016, and OR, 1.053; 95%
I, 1.006–1.092, p = 0.035, respectively].
The following variables were tested to determine the indepen-
ent predictors of %NC volume reduction at follow-up (variables
ith p < 0.1 in univariable analysis): reduction in hs-CRP ≥1 mg/dl
t follow-up, diabetes mellitus, baseline PAV, baseline %NC vol-
me. Reduction in hs-CRP ≥1 mg/dl at follow-up and baseline
NC volume were the independent predictors for %NC volume
eduction at follow-up (OR, 2.204; 95% CI, 1.512–2.916, p = 0.020,
nd OR, 1.068; 95% CI, 1.011–1.120, p = 0.033, respectively).ology 60 (2012) 277–282
4. Discussion
The present VH-IVUS study demonstrated that (1) absolute and
%NC volumes were signiﬁcantly greater in patients with reduc-
tion in hs-CRP ≥1 mg/dl compared with those with reduction
in hs-CRP ≥1 mg/dl, (2) plaque volume decreased more signiﬁ-
cantly in patients with reduction in hs-CRP ≥1 mg/dl compared
with those with reduction in hs-CRP <1 mg/dl, (3) NC component
decreased more signiﬁcantly in patients with reduction in hs-CRP
≥1 mg/dl compared with those with reduction in hs-CRP <1 mg/dl.
The plaque regression and compositional changes (decrease of NC)
by usual dose of pitavastatin treatment were more signiﬁcantly
observed in patients with reduction in hs-CRP ≥1 mg/dl compared
with those with reduction in hs-CRP <1 mg/dl in AMI  patients.
CRP has emerged as a simple tool for detecting systemic inﬂam-
mation [7,8]. An elevated CRP level is associated with an increased
risk of future fatal or nonfatal ischemic complications in acute coro-
nary syndrome patients [16–21].  A previous study demonstrated
that CRP was strongly associated with atherosclerosis measured
at various sites in the arterial tree [22]. Several mechanisms have
been described by which CRP and other inﬂammatory mediators
may  be actively involved in atherogenesis [23]. CRP is produced by
smooth muscle cells of atherosclerotic lesions [24], and the locally
produced CRP could directly participate in atherogenesis and the
development of cardiovascular complications.
Several IVUS studies have demonstrated the beneﬁts of statin
therapy to be involved in regression or no progression of coronary
plaque size [25,2,26]. Recently, the beneﬁcial effects of pitavastatin
on plaque regression or stabilization have been reported [27,28].
The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvas-
tatin in Acute Coronary Syndrome) study [27] randomly assigned
patients to receive either 4 mg/day of pitavastatin or 20 mg/day
of atorvastatin and resulted in signiﬁcant regression of coro-
nary plaque volume in both pitavastatin and atorvastatin groups.
Kodama et al. [28] assessed coronary plaque regression and sta-
bilization following 52 weeks of pitavastatin treatment (2 mg/day)
and showed that ﬁxed-dose pitavastatin stabilized vulnerable coro-
nary plaques by the reduction of yellow grade without signiﬁcant
reduction of plaque volume. Another issue is the different effects on
plaque progression using high doses of different statins. The Study
of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosu-
vastatin vs. AtorvastatiN (SATURN) [29] randomized patients to
receive rosuvastatin 40 mg  or atorvastatin 80 mg for 24 months and
it will determine whether high-dose statins have different effects
on plaque progression.
However, conventional gray-scale IVUS has limitations in
assessing plaque components. Recently, VH-IVUS, integrated
backscatter-IVUS, and iMap-IVUS with radiofrequency 40 MHz
IVUS imaging systems have been used for tissue characterization
[30,31]. VH-IVUS has the potential to provide detailed qualita-
tive and quantitative information and it can identify four speciﬁc
plaque components. Plaque components may play a role in the
plaque disruption and thrombosis that leads to acute coronary
events [32–35].  Lesions with a large lipid core may  have a higher
risk for disruption than sclerotic plaques [35–37].  Previous studies
have demonstrated that statin treatment might result in changes
of plaque composition (signiﬁcant reduction in NC volume and
increase in FF plaque volume) by VH-IVUS analysis as well as reduc-
tion in plaque volume by gray-scale IVUS analysis [38]. Recently,
Hattori et al. [39] reported that 4 mg  of pitavastatin treatment
induced favorable plaque morphologic changes with an increase in
ﬁbrous cap thickness, and decreases in both percentage plaque and
lipid volume indexes assessed by serial optical coherence tomogra-
phy, grayscale, and integrated backscatter-IVUS. The hypothesis in
the present study was  that standard dose of pitavastatin (2 mg/day)
could regress and stabilize the plaque effectively and these changes
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[
[
[
[Y.J. Hong et al. / Journal of
n the plaque characteristics might be affected by the degree of the
eduction of hs-CRP by pitavastatin treatment.
CRP renders oxidized low-density lipoprotein more susceptible
o uptake by macrophages, induces the expression of vascular-
ell adhesion molecules, stimulates the production of tissue factor,
nd impairs the production of nitric oxide [40–43].  Previous stud-
es have demonstrated the association between CRP and effect of
tatin treatment. McMurray et al. [44] reported a signiﬁcant inter-
ction between hs-CRP and the effect of rosuvastatin for primary
ndpoint including cardiovascular death, MI,  or stroke, whereby
osuvastatin treatment was associated with better outcomes in
atients with hs-CRP ≥2.0 mg/l. Nissen et al. [45] reported that the
ecrease in CRP levels was independently and signiﬁcantly corre-
ated with the rate of progression by intensive statin therapy. In
he present study, plaque change (the decrease of plaque volume
s well as plaque composition of NC) was observed more signif-
cantly in patients with reduction in hs-CRP ≥1 mg/dl compared
ith those with reduction in hs-CRP <1 mg/dl. These results sug-
est that the reduction in hs-CRP levels especially in AMI  patients
lays an important role in the beneﬁcial effects of statins on the
rogression and compositional change of coronary plaque.
. Study limitations
First, the present study was based on a small sample, thus rais-
ng the possibility of selection bias. Second, gray-scale and VH-IVUS
ere performed at the discretion of the individual operators lead-
ng to potential selection bias. Third, there are some problems
n 3-dimensional measurements when we use this type of IVUS
ystem especially at severely calciﬁed segment or branch carina.
ourth, heavily calciﬁed plaques may  induce an artifact regarding
he codiﬁcation of plaques by VH-IVUS resulting in an increase in
C content. Fifth, the mean follow-up period was  only 8 months;
onger-term IVUS follow-up data were not collected.
. Conclusions
The changes in plaque volume and composition (decrease of NC)
y usual dose of pitavastatin treatment were observed more sig-
iﬁcantly in patients with greater reduction in hs-CRP compared
ith those with lesser reduction in hs-CRP in AMI patients in this
AMIS-IVUS substudy.
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